Literature DB >> 2190094

Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding.

P A Roche1, P Cresswell.   

Abstract

Class II major histocompatibility complex (MHC) molecules are heterodimeric cell surface glycoproteins which bind and present immunogenic peptides to T lymphocytes. Such peptides are normally derived from protein antigens internalized and proteolytically degraded by the antigen-presenting cell. Class I MHC molecules also bind immunogenic peptides, but these are derived from proteins synthesized within the target cell. Whereas class I molecules seem to bind peptides in the endoplasmic reticulum, class II molecules are thought to bind peptides late in transport. Intracellular class II molecules associate in the endoplasmic reticulum with a third glycoprotein, the invariant (I) chain, which is proteolytically removed before cell surface expression of the alpha beta class II heterodimer. It has been suggested that the I chain prevents peptides from associating with class II molecules early in transport. Preventing such binding until the class II molecules enter an endosomal compartment could maintain the functional dichotomy between class I and class II MHC molecules. We have examined the ability of I chain-associated HLA-DR5 molecules to bind a well characterized influenza haemagglutinin-derived peptide (HAp). The results show that whereas mature HLA-DR alpha beta dimers effectively bind this peptide, the I chain-associated form does not.

Mesh:

Substances:

Year:  1990        PMID: 2190094     DOI: 10.1038/345615a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  147 in total

1.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

2.  Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.

Authors:  G Moldenhauer; C Henne; J Karhausen; P Möller
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

3.  Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins.

Authors:  D R Karp; R N Jenkins; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

4.  Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes.

Authors:  Valentina Zavasnik-Bergant; Ana Schweiger; Tadeja Bevec; Rastko Golouh; Vito Turk; Janko Kos
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

5.  Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules.

Authors:  M S Anderson; J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

6.  An invariant road to cross-presentation.

Authors:  Fei Duan; Pramod K Srivastava
Journal:  Nat Immunol       Date:  2012-02-16       Impact factor: 25.606

7.  Class II major histocompatibility complex molecules of murine dendritic cells: synthesis, sialylation of invariant chain, and antigen processing capacity are down-regulated upon culture.

Authors:  E Kämpgen; N Koch; F Koch; P Stöger; C Heufler; G Schuler; N Romani
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

8.  A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination.

Authors:  Liusong Yin; Lawrence J Stern
Journal:  J Immunol Methods       Date:  2014-02-25       Impact factor: 2.303

9.  Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers.

Authors:  Cheryl L Day; Nilufer P Seth; Michaela Lucas; Heiner Appel; Laurent Gauthier; Georg M Lauer; Gregory K Robbins; Zbigniew M Szczepiorkowski; Deborah R Casson; Raymond T Chung; Shannon Bell; Gillian Harcourt; Bruce D Walker; Paul Klenerman; Kai W Wucherpfennig
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

Authors:  S Baskar; S Ostrand-Rosenberg; N Nabavi; L M Nadler; G J Freeman; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.